(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 79.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Verastem's revenue in 2026 is $49,585,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $9,394,570,745, with the lowest VSTM revenue forecast at $8,336,044,890, and the highest VSTM revenue forecast at $11,081,744,614. On average, 11 Wall Street analysts forecast VSTM's revenue for 2027 to be $16,979,823,264, with the lowest VSTM revenue forecast at $14,284,738,756, and the highest VSTM revenue forecast at $24,755,761,579.
In 2028, VSTM is forecast to generate $25,507,081,193 in revenue, with the lowest revenue forecast at $20,108,124,812 and the highest revenue forecast at $33,484,250,141.